taqman® snp genotyping sequenom® massarray (Sequenom)
Structured Review

Taqman® Snp Genotyping Sequenom® Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sequenom+massarray+snp+genotyping/taqman+snp+genotyping+assay/pmc11843099-32-6-9
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Forensic DNA phenotyping: a review on SNP panels, genotyping techniques, and prediction models"
Article Title: Forensic DNA phenotyping: a review on SNP panels, genotyping techniques, and prediction models
Journal: Forensic Sciences Research
doi: 10.1093/fsr/owae013
Figure Legend Snippet: Non-commercial bio-geographical ancestry (BGA) panels proposed in the literature, including their reference article, number and ancestry informative SNPs (AISNPs) type, first used genotyping technology and prediction model, inferred populations, and related articles.
Techniques Used: Sequencing, Multiplex Assay
Figure Legend Snippet: Commercial and non-commercial externally visible characteristics (EVC) panels proposed in the literature, including their reference article, number of phenotypic-informative SNPs (PISNPs), first used genotyping technology and prediction model, inferred traits, and related articles
Techniques Used: Sequencing, Microarray
Related Articles
other:Article Title: Forensic DNA phenotyping: a review on SNP panels, genotyping techniques, and prediction models Article Snippet: [ ] , 74 aSNPs , TaqMan SNP genotyping Sequenom MassARRAY , NB (STRUCTURE) , 10 populations (sub-Saharan AFR and NAF, EUR, SWAS, NAS, SAS, EAS, SEAS, OCE, NAM) , [ ] . Article Title: A novel haplotype of low-frequency variants in the aldosterone synthase gene among northern Han Chinese with essential hypertension Article Snippet: Genotyping was performed using the TaqMan SNP genotyping assay (Sequenom Company). Article Title: Analysis of the association between Fc receptor family gene polymorphisms and ocular Behçet’s disease in Han Chinese Article Snippet: Twenty-three SNPs were genotyped using the Article Title: <p>Pharmacogene Variation in Thai <em>Plasmodium vivax</em> Relapse Patients Treated with a Combination of Primaquine and Chloroquine</p> Article Snippet: Patients and Methods: Fifty-one patients were genotyped for 74 variants in 18 genes by Sequenom MassARRAY® and Taqman® SNP Real-Time PCR. Article Title: Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine Article Snippet: Fifty-one patients were genotyped for 74 variants in 18 genes by Article Title: Forensic DNA phenotyping: a review on SNP panels, genotyping techniques, and prediction models. Article Snippet: Continued AISNPs Genotyping technology Statistical model Inferred BGA Related articles [68] 142 aSNPs Not used NB (Snipper and STRUCTURE) MLR GDA 4 populations (AFR, EUR, EAS, NAM) [199] [67] 93 aSNPs Not used NN 7 populations (AFR, EUR, CSAS, MEA, EAS, NAM, OCE) NA Japaneseplex [244] 60 aSNPs SNaPshotTM + CE NB (Snipper) EAS sub-populations NA SWA AISNP panel [58] 86 aSNPs TaqMan® SNP genotyping NB (STRUCTURE) SWAS and MED sub-populations [240] EUROFORGEN NAME [79] 111 aSNPs Sequenom® MassARRAY® NB (Snipper and STRUCTURE) NAF and MES [185] [167] 48 aSNPs Not used NB (ADMIXTURE) MLR Chinese sub-populations (Uygur, Han, Mongolian) NA Population Informative Multiplex for the Americas (PIMA) [76] 26 aSNPs SNaPshotTM + CE PCA, NB (Snipper) NAM sub-populations [245] Multiple AISNPs panel [65] 7 Y-SNPs, 12 mt-SNPs, 6 aSNPs SNaPshotTM + CE HRM NB (STRUCTURE) 2 populations (ASN and EUR) NA [246] 31 aSNPs, 21 InDels SNaPshotTM + CE NB (Snipper and STRUCTURE) 5 populations (AFR, EAS, MES, EUR, CSAS) NA Pacifiplex [75] 27 aSNPs, 2 X-SNPs SNaPshotTM + CE NB (Snipper and STRUCTURE) OCE sub-populations [187, 188, 236] MAPlex [247, 248] 144 aSNPs, 20 MH NGS NB (Snipper and STRUCTURE) 3 populations (EAS, SAS, NOCE) [249] EUR: European (NEU: North); AFR: African (WAF: West, NAF: North, NEAF: North-east); ASN: Asian (EAS: East, WEAS: West–east, SAS: South, SWAS: South-west, SEAS: South-east, central-south, NAS: North); EURAS: Eurasian; NAM: Native American; AUS: Australian; OCE: Oceanian (NOCE: Near); PAC: Pacific; NES: Near East; MES: Middle East; MED: Mediterranean; NGS: next generation sequencing; MDS: multidimensional scaling; CRT: classification and regression tree; GDA: genetic distance algorithm; NJ: neighbour joining tree; NB: Naive Bayes; ML: Machine learning; MLR: Multinomial linear regression; SVM: support vector machine; CSAS: central-south Asian; MES: middle eastern; NA: not applicable/available. Control:Article Title: Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Article Snippet: .. M AN US CR IP T AC CE PT ED 12 IBD CD UC Control IBD CD UC Control IBD CD UC Control No. of samples 1,505 922 583 4,041 1,989 993 996 3,491 3,494 1,915 1,579 7,532 Male (%) 976 (64.9) 651 (70.6) 325 (55.7) 1,602 (39.6) 1,275 (64.1) 723 (72.8) 552 (55.4) 1,771 (50.7) 2,251 (64.4) 1,374 (71.7) 877 (55.5) 3,373 (44.8) Mean age at sampling (yr) 31.1 ± 13.6 25.5 ± 9.1 40.1 ± 14.7 NA 34.9 ± 13.6 28.5 ± 9.4 41.3 ± 14.2 NA 33.3 ± 13.7 27.0 ± 9.4 40.8 ± 14.4 NA Mean age at diagnosis (yr) 27.6 ± 12.6 22.3 ± 8.2 36.0 ± 13.8 31.1 ± 12.8 25.4 ± 8.7 36.8 ± 13.7 29.6 ± 12.9 23.9 ± 8.6 36.5 ± 13.7 Age group at diagnosis (%) ≤ 16 302 (20.1) 249 (27.0) 53 (9.1) NA 114 (5.7) 80 (8.1) 34 (3.4) NA 416 (11.9) 329 (17.2) 87 (5.5) NA 17∼40 917 (60.9) 634 (68.8) 283 (48.5) NA 1,419 (71.3) 841 (84.7) 578 (58.0) NA 2,336 (66.9) 1,475 (77.0) 861 (54.5) NA ≥ 40 286 (19.0) 39 (4.2) 247 (42.4) NA 456 (22.9) 72 (7.3) 384 (38.6) NA 742 (21.2) 111 (5.8) 631 (40.0) NA Location, no. (%) Ileum 161 (19.4) 228 (23.0) 389 (21.4) Colon 45 (5.4) 36 (3.6) 81 (4.5) Ileocolon 623 (75.2) 726 (73.3) 1,349 (74.2) NA 93 3 96 Extent, no. (%) Proctitis 160 (29.4) 260 (26.3) 420 (27.4) Left-sided colitis 176 (32.4) 321 (32.5) 497 (32.4) Extensive colitis 208 (38.2) 407 (41.2) 615 (40.1) NA 39 8 47 Behavior, no. (%) Inflammatory 325 (39.2) 453 (45.6) 778 (42.7) Stricturing 164 (19.8) 186 (18.7) 350 (19.2) Penetrating 341 (41.1) 354 (35.6) 695 (38.1) NA 92 92 Perianal fistula, no. (%) No 329 (39.6) 456 (45.9) 785 (43.1) Yes 501 (60.4) 537 (54.1) 1,038 (56.9) NA 92 92 GWAS set 1 Illumina chip OmniExpress12v1 Omni1-Quad No. of samples 915 532 383 745 GWAS set 2 Illumina chip HumanOmniExpressExome8v1 Omni1-Quad No. of samples 590 390 200 3,296 Replication set Genotyping technology Sequenom iPLEX, Sampling:Article Title: Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Article Snippet: .. M AN US CR IP T AC CE PT ED 12 IBD CD UC Control IBD CD UC Control IBD CD UC Control No. of samples 1,505 922 583 4,041 1,989 993 996 3,491 3,494 1,915 1,579 7,532 Male (%) 976 (64.9) 651 (70.6) 325 (55.7) 1,602 (39.6) 1,275 (64.1) 723 (72.8) 552 (55.4) 1,771 (50.7) 2,251 (64.4) 1,374 (71.7) 877 (55.5) 3,373 (44.8) Mean age at sampling (yr) 31.1 ± 13.6 25.5 ± 9.1 40.1 ± 14.7 NA 34.9 ± 13.6 28.5 ± 9.4 41.3 ± 14.2 NA 33.3 ± 13.7 27.0 ± 9.4 40.8 ± 14.4 NA Mean age at diagnosis (yr) 27.6 ± 12.6 22.3 ± 8.2 36.0 ± 13.8 31.1 ± 12.8 25.4 ± 8.7 36.8 ± 13.7 29.6 ± 12.9 23.9 ± 8.6 36.5 ± 13.7 Age group at diagnosis (%) ≤ 16 302 (20.1) 249 (27.0) 53 (9.1) NA 114 (5.7) 80 (8.1) 34 (3.4) NA 416 (11.9) 329 (17.2) 87 (5.5) NA 17∼40 917 (60.9) 634 (68.8) 283 (48.5) NA 1,419 (71.3) 841 (84.7) 578 (58.0) NA 2,336 (66.9) 1,475 (77.0) 861 (54.5) NA ≥ 40 286 (19.0) 39 (4.2) 247 (42.4) NA 456 (22.9) 72 (7.3) 384 (38.6) NA 742 (21.2) 111 (5.8) 631 (40.0) NA Location, no. (%) Ileum 161 (19.4) 228 (23.0) 389 (21.4) Colon 45 (5.4) 36 (3.6) 81 (4.5) Ileocolon 623 (75.2) 726 (73.3) 1,349 (74.2) NA 93 3 96 Extent, no. (%) Proctitis 160 (29.4) 260 (26.3) 420 (27.4) Left-sided colitis 176 (32.4) 321 (32.5) 497 (32.4) Extensive colitis 208 (38.2) 407 (41.2) 615 (40.1) NA 39 8 47 Behavior, no. (%) Inflammatory 325 (39.2) 453 (45.6) 778 (42.7) Stricturing 164 (19.8) 186 (18.7) 350 (19.2) Penetrating 341 (41.1) 354 (35.6) 695 (38.1) NA 92 92 Perianal fistula, no. (%) No 329 (39.6) 456 (45.9) 785 (43.1) Yes 501 (60.4) 537 (54.1) 1,038 (56.9) NA 92 92 GWAS set 1 Illumina chip OmniExpress12v1 Omni1-Quad No. of samples 915 532 383 745 GWAS set 2 Illumina chip HumanOmniExpressExome8v1 Omni1-Quad No. of samples 590 390 200 3,296 Replication set Genotyping technology Sequenom iPLEX, Biomarker Discovery:Article Title: Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Article Snippet: .. M AN US CR IP T AC CE PT ED 12 IBD CD UC Control IBD CD UC Control IBD CD UC Control No. of samples 1,505 922 583 4,041 1,989 993 996 3,491 3,494 1,915 1,579 7,532 Male (%) 976 (64.9) 651 (70.6) 325 (55.7) 1,602 (39.6) 1,275 (64.1) 723 (72.8) 552 (55.4) 1,771 (50.7) 2,251 (64.4) 1,374 (71.7) 877 (55.5) 3,373 (44.8) Mean age at sampling (yr) 31.1 ± 13.6 25.5 ± 9.1 40.1 ± 14.7 NA 34.9 ± 13.6 28.5 ± 9.4 41.3 ± 14.2 NA 33.3 ± 13.7 27.0 ± 9.4 40.8 ± 14.4 NA Mean age at diagnosis (yr) 27.6 ± 12.6 22.3 ± 8.2 36.0 ± 13.8 31.1 ± 12.8 25.4 ± 8.7 36.8 ± 13.7 29.6 ± 12.9 23.9 ± 8.6 36.5 ± 13.7 Age group at diagnosis (%) ≤ 16 302 (20.1) 249 (27.0) 53 (9.1) NA 114 (5.7) 80 (8.1) 34 (3.4) NA 416 (11.9) 329 (17.2) 87 (5.5) NA 17∼40 917 (60.9) 634 (68.8) 283 (48.5) NA 1,419 (71.3) 841 (84.7) 578 (58.0) NA 2,336 (66.9) 1,475 (77.0) 861 (54.5) NA ≥ 40 286 (19.0) 39 (4.2) 247 (42.4) NA 456 (22.9) 72 (7.3) 384 (38.6) NA 742 (21.2) 111 (5.8) 631 (40.0) NA Location, no. (%) Ileum 161 (19.4) 228 (23.0) 389 (21.4) Colon 45 (5.4) 36 (3.6) 81 (4.5) Ileocolon 623 (75.2) 726 (73.3) 1,349 (74.2) NA 93 3 96 Extent, no. (%) Proctitis 160 (29.4) 260 (26.3) 420 (27.4) Left-sided colitis 176 (32.4) 321 (32.5) 497 (32.4) Extensive colitis 208 (38.2) 407 (41.2) 615 (40.1) NA 39 8 47 Behavior, no. (%) Inflammatory 325 (39.2) 453 (45.6) 778 (42.7) Stricturing 164 (19.8) 186 (18.7) 350 (19.2) Penetrating 341 (41.1) 354 (35.6) 695 (38.1) NA 92 92 Perianal fistula, no. (%) No 329 (39.6) 456 (45.9) 785 (43.1) Yes 501 (60.4) 537 (54.1) 1,038 (56.9) NA 92 92 GWAS set 1 Illumina chip OmniExpress12v1 Omni1-Quad No. of samples 915 532 383 745 GWAS set 2 Illumina chip HumanOmniExpressExome8v1 Omni1-Quad No. of samples 590 390 200 3,296 Replication set Genotyping technology Sequenom iPLEX, GWAS:Article Title: Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Article Snippet: .. M AN US CR IP T AC CE PT ED 12 IBD CD UC Control IBD CD UC Control IBD CD UC Control No. of samples 1,505 922 583 4,041 1,989 993 996 3,491 3,494 1,915 1,579 7,532 Male (%) 976 (64.9) 651 (70.6) 325 (55.7) 1,602 (39.6) 1,275 (64.1) 723 (72.8) 552 (55.4) 1,771 (50.7) 2,251 (64.4) 1,374 (71.7) 877 (55.5) 3,373 (44.8) Mean age at sampling (yr) 31.1 ± 13.6 25.5 ± 9.1 40.1 ± 14.7 NA 34.9 ± 13.6 28.5 ± 9.4 41.3 ± 14.2 NA 33.3 ± 13.7 27.0 ± 9.4 40.8 ± 14.4 NA Mean age at diagnosis (yr) 27.6 ± 12.6 22.3 ± 8.2 36.0 ± 13.8 31.1 ± 12.8 25.4 ± 8.7 36.8 ± 13.7 29.6 ± 12.9 23.9 ± 8.6 36.5 ± 13.7 Age group at diagnosis (%) ≤ 16 302 (20.1) 249 (27.0) 53 (9.1) NA 114 (5.7) 80 (8.1) 34 (3.4) NA 416 (11.9) 329 (17.2) 87 (5.5) NA 17∼40 917 (60.9) 634 (68.8) 283 (48.5) NA 1,419 (71.3) 841 (84.7) 578 (58.0) NA 2,336 (66.9) 1,475 (77.0) 861 (54.5) NA ≥ 40 286 (19.0) 39 (4.2) 247 (42.4) NA 456 (22.9) 72 (7.3) 384 (38.6) NA 742 (21.2) 111 (5.8) 631 (40.0) NA Location, no. (%) Ileum 161 (19.4) 228 (23.0) 389 (21.4) Colon 45 (5.4) 36 (3.6) 81 (4.5) Ileocolon 623 (75.2) 726 (73.3) 1,349 (74.2) NA 93 3 96 Extent, no. (%) Proctitis 160 (29.4) 260 (26.3) 420 (27.4) Left-sided colitis 176 (32.4) 321 (32.5) 497 (32.4) Extensive colitis 208 (38.2) 407 (41.2) 615 (40.1) NA 39 8 47 Behavior, no. (%) Inflammatory 325 (39.2) 453 (45.6) 778 (42.7) Stricturing 164 (19.8) 186 (18.7) 350 (19.2) Penetrating 341 (41.1) 354 (35.6) 695 (38.1) NA 92 92 Perianal fistula, no. (%) No 329 (39.6) 456 (45.9) 785 (43.1) Yes 501 (60.4) 537 (54.1) 1,038 (56.9) NA 92 92 GWAS set 1 Illumina chip OmniExpress12v1 Omni1-Quad No. of samples 915 532 383 745 GWAS set 2 Illumina chip HumanOmniExpressExome8v1 Omni1-Quad No. of samples 590 390 200 3,296 Replication set Genotyping technology Sequenom iPLEX, TaqMan SNP Genotyping Assay:Article Title: Identification of Loci at 1q21 and 16q23 That Affect Susceptibility to Inflammatory Bowel Disease in Koreans. Article Snippet: .. M AN US CR IP T AC CE PT ED 12 IBD CD UC Control IBD CD UC Control IBD CD UC Control No. of samples 1,505 922 583 4,041 1,989 993 996 3,491 3,494 1,915 1,579 7,532 Male (%) 976 (64.9) 651 (70.6) 325 (55.7) 1,602 (39.6) 1,275 (64.1) 723 (72.8) 552 (55.4) 1,771 (50.7) 2,251 (64.4) 1,374 (71.7) 877 (55.5) 3,373 (44.8) Mean age at sampling (yr) 31.1 ± 13.6 25.5 ± 9.1 40.1 ± 14.7 NA 34.9 ± 13.6 28.5 ± 9.4 41.3 ± 14.2 NA 33.3 ± 13.7 27.0 ± 9.4 40.8 ± 14.4 NA Mean age at diagnosis (yr) 27.6 ± 12.6 22.3 ± 8.2 36.0 ± 13.8 31.1 ± 12.8 25.4 ± 8.7 36.8 ± 13.7 29.6 ± 12.9 23.9 ± 8.6 36.5 ± 13.7 Age group at diagnosis (%) ≤ 16 302 (20.1) 249 (27.0) 53 (9.1) NA 114 (5.7) 80 (8.1) 34 (3.4) NA 416 (11.9) 329 (17.2) 87 (5.5) NA 17∼40 917 (60.9) 634 (68.8) 283 (48.5) NA 1,419 (71.3) 841 (84.7) 578 (58.0) NA 2,336 (66.9) 1,475 (77.0) 861 (54.5) NA ≥ 40 286 (19.0) 39 (4.2) 247 (42.4) NA 456 (22.9) 72 (7.3) 384 (38.6) NA 742 (21.2) 111 (5.8) 631 (40.0) NA Location, no. (%) Ileum 161 (19.4) 228 (23.0) 389 (21.4) Colon 45 (5.4) 36 (3.6) 81 (4.5) Ileocolon 623 (75.2) 726 (73.3) 1,349 (74.2) NA 93 3 96 Extent, no. (%) Proctitis 160 (29.4) 260 (26.3) 420 (27.4) Left-sided colitis 176 (32.4) 321 (32.5) 497 (32.4) Extensive colitis 208 (38.2) 407 (41.2) 615 (40.1) NA 39 8 47 Behavior, no. (%) Inflammatory 325 (39.2) 453 (45.6) 778 (42.7) Stricturing 164 (19.8) 186 (18.7) 350 (19.2) Penetrating 341 (41.1) 354 (35.6) 695 (38.1) NA 92 92 Perianal fistula, no. (%) No 329 (39.6) 456 (45.9) 785 (43.1) Yes 501 (60.4) 537 (54.1) 1,038 (56.9) NA 92 92 GWAS set 1 Illumina chip OmniExpress12v1 Omni1-Quad No. of samples 915 532 383 745 GWAS set 2 Illumina chip HumanOmniExpressExome8v1 Omni1-Quad No. of samples 590 390 200 3,296 Replication set Genotyping technology Sequenom iPLEX, |